<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/portal?portalId=9001&amp;quantity=&amp;format=rss&amp;version=">
        <title>BioMed Central - Latest Articles</title>
        <link>http://www.biomedcentral.com/</link>
        <description>The latest research articles published by BioMed Central</description>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.pssjournal.com/content/3/1/25" />
                                <rdf:li rdf:resource="http://www.trialsjournal.com/content/10/1/106" />
                                <rdf:li rdf:resource="http://www.harmreductionjournal.com/content/6/1/32" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6750/9/96" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2334/9/181" />
                                <rdf:li rdf:resource="http://www.parasitesandvectors.com/content/2/1/57" />
                                <rdf:li rdf:resource="http://www.casesjournal.com/content/2/1/9072" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2164/10/549" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/143" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2407/9/406" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.pssjournal.com/content/3/1/25">
        <title>Improving operating room safety</title>
        <description>Despite the introduction of the Universal Protocol, patient safety in surgery remains a daily challenge in the operating room.  This present study describes one community health system&apos;s efforts to improve operating room safety through human factors training and ultimately the development of a surgical checklist. Using a combination of formal training, local studies documenting operating room safety issues and peer to peer mentoring we were able to substantially change the culture of our operating room.  Our efforts have prepared us for successfully implementing a standardized checklist to improve operating room safety throughout our entire system.  Based on these findings we recommend a multimodal approach to improving operating room safety.</description>
        <link>http://www.pssjournal.com/content/3/1/25</link>
                <dc:creator>Scott Hurlbert</dc:creator>
                <dc:creator>Jill Garrett</dc:creator>
                <dc:source>Patient Safety in Surgery 2009, 3:25</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1754-9493-3-25</dc:identifier>
        <prism:publicationName>Patient Safety in Surgery</prism:publicationName>
        <prism:issn>1754-9493</prism:issn>
        <prism:volume>3</prism:volume>
        <prism:startingPage>25</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.trialsjournal.com/content/10/1/106">
        <title>Quality of reporting of randomized controlled trials in polycystic ovary syndrome

</title>
        <description>Background:
Inadequate reporting of randomized controlled trials (RCTs) is associated with biased estimates of treatment effects. The reporting quality of RCTs involving patients with polycystic ovary syndrome (PCOS) is unknown. The purpose of this study was to assess the reporting quality of RCTs involving patients with PCOS using a standardized tool based on the Consolidated Standards of Reporting Trials (CONSORT) statement.
Methods:
We searched PubMed database for English-language RCTs involving patients with PCOS. Quality of reporting was assessed using a 24-item questionnaire based on the revised CONSORT checklist. Reporting was evaluated overall, and for pre- and post-CONSORT periods. RCTs on PCOS associated with fertility and non-fertility disturbances were also evaluated separately.
Results:
Nine of the 24 items were reported in less than 50% of the studies, while a significant improvement (P&lt;0.05) was detected in 12 of 24 items (50%) over the two CONSORT periods. The RCTs on PCOS with reference to fertility seem to have adhered better to CONSORT statement than RCTs not associated to fertility.
Conclusions:
There is empirical evidence of suboptimal reporting quality of RCTs in PCOS. Endorsement of the CONSORT statement may optimize the reporting quality and enhance the validity of research.</description>
        <link>http://www.trialsjournal.com/content/10/1/106</link>
                <dc:creator>Anna Partsinevelou</dc:creator>
                <dc:creator>Elias Zintzaras</dc:creator>
                <dc:source>Trials 2009, 10:106</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1745-6215-10-106</dc:identifier>
        <prism:publicationName>Trials</prism:publicationName>
        <prism:issn>1745-6215</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>106</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.harmreductionjournal.com/content/6/1/32">
        <title>Integrated programs for women with substance use issues and their children: a qualitative meta-synthesis of processes and outcomes</title>
        <description>Background:
There is a need for services that effectively and comprehensively address the complex needs of women with substance use issues and their children. A growing body of literature supports the relevance of integrated treatment programs that offer a wide range of services in centralized settings. Quantitative studies suggest that these programs are associated with positive outcomes. A qualitative meta-synthesis was conducted to provide insight into the processes that contribute to recovery in integrated programs and women&apos;s perceptions of benefits for themselves and their children.
Methods:
A comprehensive search of published and unpublished literature to August 2009 was carried out for narrative reports of women&apos;s experiences and perceptions of integrated treatment programs. Eligibility for inclusion in the meta-synthesis was determined using defined criteria. Quality assessment was then conducted. Qualitative data and interpretations were extracted from studies of adequate quality, and were synthesized using a systematic and iterative process to create themes and overarching concepts.
Results:
A total of 15 documents were included in the meta-synthesis. Women experienced a number of psychosocial processes during treatment that played a role in their recovery and contributed to favourable outcomes. These included: development of a sense of self; development of personal agency; giving and receiving of social support; engagement with program staff; self-disclosure of challenges, feelings, and past experiences; recognizing patterns of destructive behaviour; and goal setting. A final process, the motivating presence of children, sustained women in their recovery journeys. Perceived outcomes included benefits for maternal and child well-being, and enhanced parenting capacity.
Conclusions:
A number of distinct but interconnected processes emerged as being important to women&apos;s addiction recovery. Women experienced individual growth and transformative learning that led to a higher quality of life and improved interactions with their children. The findings support the need for programs to adopt practices that focus on improving maternal health and social functioning in an environment characterized by empowerment, safety, and connections. Women&apos;s relationships with their children require particular attention as positive parenting practices and family relationships can alter predispositions toward substance use later in life, thereby impacting favourably on the cycle of addiction and dysfunctional parenting.</description>
        <link>http://www.harmreductionjournal.com/content/6/1/32</link>
                <dc:creator>Wendy Sword</dc:creator>
                <dc:creator>Susan Jack</dc:creator>
                <dc:creator>Alison Niccols</dc:creator>
                <dc:creator>Karen Milligan</dc:creator>
                <dc:creator>Joanna Henderson</dc:creator>
                <dc:creator>Lehana Thabane</dc:creator>
                <dc:source>Harm Reduction Journal 2009, 6:32</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-7517-6-32</dc:identifier>
        <prism:publicationName>Harm Reduction Journal</prism:publicationName>
        <prism:issn>1477-7517</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>32</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6750/9/96">
        <title>High-level HIV-1 Nef transient expression in Nicotiana benthamiana using the P19 gene silencing suppressor protein of Artichoke Mottled Crinckle Virus </title>
        <description>Background:
In recent years, different HIV antigens have been successfully expressed in plants by either stable transformation or transient expression systems. Among HIV proteins, Nef is considered a promising target for the formulation of a multi-component vaccine due to its implication in the first steps of viral infection. Attempts to express Nef as a single protein product (not fused to a stabilizing protein) in transgenic plants resulted in disappointingly low yields (about 0.5% of total soluble protein). In this work we describe a transient expression system based on co-agroinfiltration of plant virus gene silencing suppressor proteins in Nicotiana benthamiana, followed by a two-step affinity purification protocol of plant-derived Nef.
Results:
The effect of three gene silencing viral suppressor proteins (P25 of Potato Virus X, P19 of  either Artichoke Mottled Crinckle virus and Tomato Bushy Stunt virus) on Nef transient expression yield was evaluated. The P19 protein of Artichoke Mottled Crinckle virus (AMCV-P19) gave the highest expression yield in vacuum co-agroinfiltration experiments reaching 1.3% of total soluble protein, a level almost three times higher than that previously reported in stable transgenic plants. The high yield observed in the co-agroinfiltrated plants was correlated to a remarkable decrease of Nef-specific small interfering RNAs (siRNAs) indicating an effective modulation of RNA silencing mechanisms by AMCV-P19. Interestingly, we also showed that expression levels in top leaves of vacuum co-agroinfiltrated plants were noticeably reduced compared to bottom leaves. Moreover, purification of Nef from agroinfiltrated tissue was achieved by a two-step immobilized metal ion affinity chromatography protocol with yields of 250 ng/g of fresh tissue.
Conclusions:
We demonstrated that expression level of HIV-1 Nef in plant can be improved using a transient expression system enhanced by the AMCV-P19 gene silencing suppressor protein. Moreover, plant-derived Nef was purified, with enhanced yield, exploiting a two-step purification protocol. These results represent a first step towards the development of a plant-derived HIV vaccine.</description>
        <link>http://www.biomedcentral.com/1472-6750/9/96</link>
                <dc:creator>Raffaele Lombardi</dc:creator>
                <dc:creator>Patrizia Circelli</dc:creator>
                <dc:creator>Maria Elena Villani</dc:creator>
                <dc:creator>Giampaolo Buriani</dc:creator>
                <dc:creator>Luca Nardi</dc:creator>
                <dc:creator>Valentina Coppola</dc:creator>
                <dc:creator>Linda Bianco</dc:creator>
                <dc:creator>Eugenio Benvenuto</dc:creator>
                <dc:creator>Marcello Donini</dc:creator>
                <dc:creator>Carla Marusic</dc:creator>
                <dc:source>BMC Biotechnology 2009, 9:96</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6750-9-96</dc:identifier>
        <prism:publicationName>BMC Biotechnology</prism:publicationName>
        <prism:issn>1472-6750</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>96</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2334/9/181">
        <title>Inequitable childhood immunization uptake in Nigeria: A multilevel analysis of individual and contextual determinants.</title>
        <description>Background:
Immunization coverage in many parts of Nigeria is far from optimal, and far from equitable.Nigeria accounts for half of the deaths from Measles in Africa, the highest prevalence of circulating wild poliovirus in the world, and the country is among the ten countries in the world with vaccine coverage below 50 percent. Studies focusing on community-level determinants therefore have serious policy implications
Methods:
Multilevel multivariable regression analysis was used on a nationally-representative sample of women aged 15-49 years from the 2003 Nigeria Demographic and Health Survey. Multilevel regression analysis was performed with children (level 1) nested within mothers (level 2), who were in turn nested within communities (level 3).
Results:
Results show that the pattern of full immunization clusters within families and communities, and that socio-economic characteristics were important in explaining the differentials in full immunization among the children in the study. At the individual level, ethnicity, mothers&apos; occupation, and mothers&apos; household wealth were characteristics of the mothers associated with full immunization of the children. At the community level, the proportion of mothers that had hospital delivery was a determinant of full immunization status.
Conclusion:
Significant community-level variation remaining after having controlled for child- and mother-level characteristics is indicative of a need for further research on community-levels factors, which would enable extensive tailoring of community-level interventions aimed at improving full immunization and other child health outcomes.</description>
        <link>http://www.biomedcentral.com/1471-2334/9/181</link>
                <dc:creator>Diddy Antai</dc:creator>
                <dc:source>BMC Infectious Diseases 2009, 9:181</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2334-9-181</dc:identifier>
        <prism:publicationName>BMC Infectious Diseases</prism:publicationName>
        <prism:issn>1471-2334</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>181</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.parasitesandvectors.com/content/2/1/57">
        <title>Silencing of a putative immunophilin gene in the cattle tick Rhipicephalus (Boophilus) microplus increases the infection rate of Babesia bovis in larval progeny</title>
        <description>Background:
The cattle tick Rhipicephalus (Boophilus) microplus is involved in the transmission of the protozoan Babesia bovis, the etiological agent of bovine babesiosis. Interactions between ticks and protozoa are poorly understood and the investigation of tick genes that affect tick fitness and protozoan infection can set the stage for dissecting the molecular interactions between the two species.
Results:
In this study, RNA interference was used to silence R. microplus genes that had been previously shown to be up-regulated in response to B. bovis infection. The silencing of a putative immunophilin gene (Imnp) in female ticks fed on a calf acutely infected with B. bovis decreased the hatching rate and survival of larval progeny. Interestingly, Imnp was up-regulated significantly in ovaries of R. microplus in response to B. bovis infection and its silencing in female ticks significantly increased the infection rate of the protozoan in larval progeny. The results also showed that the silencing of a putative Kunitz-type serine protease inhibitor (Spi) gene and a putative lipocalin (Lpc) gene decreased the fitness of R. microplus females, but had no significant effect on the infection rate of B. bovis in larval progeny.
Conclusion:
The silencing of the Imnp, Spi or Lpc genes decreased the fitness of R. microplus females fed on a calf during acute B. bovis infection. The Imnp gene data suggest that this putative immunophilin gene is involved in the defense system of R. microplus against B. bovis and may play a role in controlling the protozoan infection in tick ovaries and larval progeny.</description>
        <link>http://www.parasitesandvectors.com/content/2/1/57</link>
                <dc:creator>Reginaldo Bastos</dc:creator>
                <dc:creator>Massaro Ueti</dc:creator>
                <dc:creator>Felix Guerrero</dc:creator>
                <dc:creator>Donald Knowles</dc:creator>
                <dc:creator>Glen Scoles</dc:creator>
                <dc:source>Parasites &amp; Vectors 2009, 2:57</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1756-3305-2-57</dc:identifier>
        <prism:publicationName>Parasites &amp; Vectors</prism:publicationName>
        <prism:issn>1756-3305</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>57</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.casesjournal.com/content/2/1/9072">
        <title>Infective endocarditis on mitral annular calcification: a case report</title>
        <description>IntroductionMitral annular calcification is a common finding in elderly patients; it is considered a benign cardiac abnormality but it can be a predisposing factor for infective endocarditis. Although described in  numerous necropsy studies, endocarditis on mitral annular calcification has rarely been reported during life, and the frequency of sepsis can be underestimated because of difficult diagnosis.Case presentationWe present a case of infective endocarditis on mitral annulus calcification in a patients with acute coronary syndrome, diagnosed with transthoracic echocardiography.
Conclusion:
Transthoracic echocardiography may contribute to a correct diagnosis, showing typical findings of infective endocarditis on mitral annular calcification in order to administrate an adequate antibiotic profilaxis in patients undergoing endoscopic or invasive procedures.</description>
        <link>http://www.casesjournal.com/content/2/1/9072</link>
                <dc:creator>Giovanni Minardi</dc:creator>
                <dc:creator>Paolo G Pino</dc:creator>
                <dc:creator>Martina Sordi</dc:creator>
                <dc:creator>Herribert Pavaci</dc:creator>
                <dc:creator>Carla Manzara</dc:creator>
                <dc:creator>Giovanni Pulignano</dc:creator>
                <dc:creator>Enrico Natale</dc:creator>
                <dc:creator>Carlo Gaudio</dc:creator>
                <dc:source>Cases Journal 2009, 2:9072</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1757-1626-2-9072</dc:identifier>
        <prism:publicationName>Cases Journal</prism:publicationName>
        <prism:issn>1757-1626</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>9072</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2164/10/549">
        <title>Novel motifs distinguish multiple homologues of Polycomb in vertebrates: expansion and diversification of the epigenetic toolkit</title>
        <description>Background:
Polycomb group (PcG) proteins maintain expression pattern of genes set early during development. Although originally isolated as regulators of homeotic genes, PcG members play a key role in epigenetic mechanism that maintains the expression state of a large number of genes. Polycomb (PC) is conserved during evolution and while invertebrates have one PC gene, vertebrates have five or more homologues. It remains unclear if different vertebrate PC homologues have distinct or overlapping functions. We have identified and compared the sequence of PC homologues in various organisms to analyze similarities and differences that shaped the evolutionary history of this key regulatory protein.
Results:
All PC homologues have an N-terminal chromodomain and a C-terminal Polycomb Repressor box. We searched the protein and genome sequence database of various organisms for these signatures and identified ~100 PC homologues. Comparative analysis of these sequences led to the identification of a novel insect specific motif and several novel and signature motifs in the vertebrate homologue: two in CBX2 (Cx2.1 and Cx2.2), four in CBX4 (Cx4.1, Cx4.2, Cx4.3 and Cx4.4), three in CBX6 (Cx6.1, Cx6.2 and Cx6.3) and one in CBX8 (Cx8.1). Additionally, adjacent to the chromodomain, all the vertebrate homologues have a DNA binding motif - AT-Hook in case of CBX2, which was known earlier, and &apos;AT-Hook Like&apos; motif, from this study, in other PC homologues.
Conclusions:
Our analysis shows that PC is an ancient gene dating back to pre bilaterian origin that has not only been conserved but has also expanded during the evolution of complexity. Unique motifs acquired by each homologue have been maintained for more than 500 millions years indicating their functional relevance in boosting the epigenetic &apos;tool kit&apos;. We report the presence of a DNA interaction motif adjacent to chromodomain in all vertebrate PC homologues and suggest a three-way &apos;PC-histoneH3-DNA&apos; interaction that can restrict nucleosome dynamics. The signature motifs of PC homologues and insect specific motif identified in this study pave the way to understand the molecular basis of epigenetic mechanisms.</description>
        <link>http://www.biomedcentral.com/1471-2164/10/549</link>
                <dc:creator>Ramamoorthy Senthilkumar</dc:creator>
                <dc:creator>Rakesh Mishra</dc:creator>
                <dc:source>BMC Genomics 2009, 10:549</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2164-10-549</dc:identifier>
        <prism:publicationName>BMC Genomics</prism:publicationName>
        <prism:issn>1471-2164</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>549</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/143">
        <title>Studying the association between musculoskeletal disorders, quality of life and mental health. A primary care pilot study in rural Crete, Greece</title>
        <description>Background:
The burden of musculoskeletal disorders (MSD) on the general health and well-being of the population has been documented in various studies. The objective of this study was to assess the impact of MSD on the quality of life and mental health of patients and to discuss issues concerning care seeking patterns in rural Greece.
Methods:
Patients registered at one rural Primary Care Centre (PCC) in Crete were invited to complete the Nordic Musculoskeletal Questionnaire (NMQ) for the analysis of musculoskeletal symptoms, together with validated instruments for measuring health related quality of life (SF-36) and mental distress (GHQ-28).
Results:
The prevalence rate of MSD was found to be 71.2%, with low back and knee pain being the most common symptoms. Most conditions significantly impaired the quality of life, especially physical dimensions of SF-36. Depression was strongly correlated to most MSD (p&lt;0.001). Multiple logistic analyses revealed that patients who consult general practitioners due to MSD were likely to have more depression or impaired physical functioning compared to those who did not.
Conclusions:
Musculoskeletal disorders were common in patients attending the rural PCC of this study and were associated with a poor quality of life and mental distress that affected their consultation behaviour.</description>
        <link>http://www.biomedcentral.com/1471-2474/10/143</link>
                <dc:creator>Maria Antonopoulou</dc:creator>
                <dc:creator>Athanasios Alegakis</dc:creator>
                <dc:creator>Alexander Hadjipavlou</dc:creator>
                <dc:creator>Christos Lionis</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:143</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-143</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>143</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2407/9/406">
        <title>The Int7G24A variant of transforming growth factor-beta receptor type I is a risk factor for colorectal cancer in the male Spanish population: a case-control study

</title>
        <description>Background:
The Int7G24A variant of transforming growth factor-beta receptor type I (TGFBR1) has been shown to increase the risk for kidney, ovarian, bladder, lung and breast cancers. Its role in colorectal cancer (CRC) has not been established. The aims of this study were to assess the association of TGFBR1*Int7G24A variant with CRC occurrence, patient age, gender, tumour location and stage.
Methods:
We performed a case-control study with 504 cases of sporadic CRC; and 504 non-cancerous age, gender and ethnically matched controls. Genotyping analysis was performed using allelic discrimination assay by real time PCR.
Results:
The Int7G24A variant was associated with increased CRC incidence in an additive model of inheritance (P for trend = 0.005). No significant differences were found between Int7G24A genotypes and tumour location or stage. Interestingly, the association of the Int7G24A variant with CRC risk was significant in men (odds ratio 4.10 with 95% confidence intervals 1.41-11.85 for homozygous individuals; P for trend = 0.00023), but not in women. We also observed an increase in susceptibility to CRC for individuals aged less than 70 years.
Conclusions:
Our data suggest that the Int7G24A variant represents a risk factor for CRC in the male Spanish population.</description>
        <link>http://www.biomedcentral.com/1471-2407/9/406</link>
                <dc:creator>Adela Castillejo</dc:creator>
                <dc:creator>Trinidad Mata-Balaguer</dc:creator>
                <dc:creator>Carla Guarinos</dc:creator>
                <dc:creator>Maria-Isabel Castillejo</dc:creator>
                <dc:creator>Ana Martinez-Canto</dc:creator>
                <dc:creator>Victor-Manuel Barbera</dc:creator>
                <dc:creator>Paola Montenegro</dc:creator>
                <dc:creator>Enrique Ochoa</dc:creator>
                <dc:creator>Rafael Lazaro</dc:creator>
                <dc:creator>Carmen Guillen-Ponce</dc:creator>
                <dc:creator>Alfredo Carrato</dc:creator>
                <dc:creator>Jose Soto</dc:creator>
                <dc:source>BMC Cancer 2009, 9:406</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2407-9-406</dc:identifier>
        <prism:publicationName>BMC Cancer</prism:publicationName>
        <prism:issn>1471-2407</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>406</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
